DOXA AB |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.63 SEK | +0.77% |
|
-4.01% | -22.76% |
| 04-10 | Doxa AB announced that it has received SEK 200 million in funding | CI |
| 02-15 | Doxa AB Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2022 | 5.3M 486K 38.76M | Sales 2023 | 9.9M 907K 72.4M | Capitalization | 1.74B 160M 12.74B |
|---|---|---|---|---|---|
| Net income 2022 | -39M -3.57M -285M | Net income 2023 | 292M 26.75M 2.14B | EV / Sales 2022 | 259 x |
| Net cash position 2022 | 52.1M 4.77M 381M | Net Debt 2023 | 94.6M 8.67M 692M | EV / Sales 2023 | 186 x |
| P/E ratio 2022 |
-34.2
x | P/E ratio 2023 |
4.52
x | Employees | 6 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 39.11% |
More Fundamentals
* Assessed data
More news
More news
| 1 day | +0.77% | ||
| 1 week | -4.01% | ||
| Current month | -15.71% | ||
| 1 month | -18.83% | ||
| 3 months | -19.69% | ||
| 6 months | -12.33% | ||
| Current year | -22.76% |
1 week
2.55
2.76
1 month
2.553.34
Current year
2.553.60
1 year
2.555.71
3 years
2.5518.40
5 years
1.8318.40
10 years
1.0118.40
| Managers | Title | Age | Since |
|---|---|---|---|
Victor Persson
CEO | Chief Executive Officer | 40 | 31/12/21 |
Patrik Melin
DFI | Director of Finance/CFO | 47 | 31/12/21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 64 | 31/12/20 | |
| Director/Board Member | 53 | 31/12/22 | |
Per Ekelund
CHM | Chairman | 53 | 31/12/20 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/04/24 | 2.63 | +0.77% | 144 019 |
| 26/04/24 | 2.61 | -1.88% | 606,469 |
| 25/04/24 | 2.66 | -1.48% | 755,299 |
| 24/04/24 | 2.7 | +0.19% | 315,270 |
| 23/04/24 | 2.695 | -1.64% | 729,562 |
Delayed Quote Nasdaq Stockholm, April 29, 2024 at 11:02 am
More quotes
Doxa AB is a Sweden-based company which develops products based on bio-active ceramics. The Company develops, manufactures and commercializes products based upon its technology platform of calcium aluminate hydrate and bioactive ceramics. Activities are divided into the therapy areas of orthopedics and odontology. Research areas within orthopedics are methods for treating fractures resulting from osteoporosis, reconstructive orthopedics and coating of implants. Research areas within odontology are tooth restoration and implant fixation.
Calendar
14/05/2024
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -22.76% | 139M | |
| +36.16% | 27.94B | |
| -13.91% | 26.97B | |
| +21.99% | 26.95B | |
| +2.14% | 25.32B | |
| +44.49% | 22.58B | |
| +2.53% | 19.59B | |
| +5.52% | 19.52B | |
| +28.54% | 16.23B | |
| -14.54% | 14.98B |
- Stock Market
- Equities
- DOXA Stock
